CN1742902A - Chinese medicinal pills for treating coronary heart disease - Google Patents
Chinese medicinal pills for treating coronary heart disease Download PDFInfo
- Publication number
- CN1742902A CN1742902A CN 200410060497 CN200410060497A CN1742902A CN 1742902 A CN1742902 A CN 1742902A CN 200410060497 CN200410060497 CN 200410060497 CN 200410060497 A CN200410060497 A CN 200410060497A CN 1742902 A CN1742902 A CN 1742902A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- treatment
- heart disease
- coronary heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a Chinese medicine pill preparation for curing coronary heart disease. It is made up by using 10 Chinese medicinal materials of mealy fanjiroot, astragalus root, tree peony bark, earthworm, salvia root and others.
Description
Technical field:
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of medicine pill for the treatment of coronary heart disease.
Background technology:
Coronary atherosclerotic heart disease (CHD) claims ischemic heart desease again, is the heart disease that causes myocardial ischemia, anoxia to cause owing to coronary atherosclerosis etc.Pilosity was born in more than 40 years old, the male is more than the women, holding pride of place among the heart disease inpatient at present, be cardiovascular Disability and dead modal fundamental cause, modern medicine is not understood as yet fully to the cause of disease of coronary heart disease, through the prompting of the sick research of waterside for many years, causing the topmost easy trouble factor of coronary heart disease is hypertension, hypercholesterolemia, high triglyceride, smoking and diabetes, it is generally acknowledged that the lipid metabolism obstacle is to cause under the endarterium the tremulous pulse that fat and fibrous tissue accumulation progressively cause and the obturation of main ramose visceral pericardium section thereof.Doctor trained in Western medicine does not still have any medicine or operative therapy at present can effectively eliminate medicated porridge sample material or dissolving speckle, treatment is advocated medicine blood vessel dilating, medicine dissolution thrombosis or is adopted the excision lesion vessels, short-term can be alleviated some symptoms, but thrombolytic medicine and anticoagulant medicine have obvious toxic and side effects, have report to claim the thrombolytic medicine can cause infraction, damage, hemorrhage more again.Can aggravate plaque rupture, cause thrombosis, the collatoral vessel after the injured blood vessel obturation is set up and the self-protection function easily.To coronary heart disease or infraction implement the arteria coronaria vascular bypass, etc. traumatic treatment can not make the conversion of atherosis blood vessel generation essence; Blood vessel dilating may be local failure; Existing medicine treatment time is long, and toxic and side effects is big.
Summary of the invention:
The objective of the invention is to design the medicine pill of the treatment coronary heart disease that a kind of curative effect is reliable, treatment time is short, toxic and side effects is little.
The present invention is made by following bulk drugs: Radix Stephaniae Tetrandrae 2-10 part, Radix Astragali 2-10 part, Cortex Moutan 1-8 part, Pheretima 1-7 part, Rhizoma Alismatis 1-8 part, Radix Puerariae 1-8 part, Radix Salviae Miltiorrhizae 1-7 part, Fructus Crataegi 1-8 part, Radix Polygoni Multiflori 1-8 part, Rhizoma Chuanxiong 1-6 part;
Preferable range: Radix Stephaniae Tetrandrae 4-8 part, Radix Astragali 4-8 part, Cortex Moutan 2-6 part, Pheretima 1-5 part, Rhizoma Alismatis 2-6 part, Radix Puerariae 2-6 part, Radix Salviae Miltiorrhizae 1-5 part, Fructus Crataegi 2-6 part, Radix Polygoni Multiflori 2-6 part, Rhizoma Chuanxiong 1-4 part.
The pathogenesis that coronary heart disease forms is thought " deficiency in origin and excess in superficiality " at present, and research thinks that deficiency in origin mainly is to be " YANG QI deficiency ", and mark actually mainly is " cloudy Tianjin is not surplus ".So, " the moon is had a surplus, YANG deficiency ", just become the main pathogenic characteristic of coronary heart disease.Body fluid is the general name of all normal water liquid of human body, refers to liquid necessary in vital movement, also is the carrier of the various materials of human body absorption.Say that from chemical constitution account for about 60% of human body greatly, wherein the content in blood is about 90%.The normal person takes in and discharges a large amount of water liquid every day, and these body fluid are very big in the intravital variation of machine, by feat of the regulation system that self had, properly regulates by physiological need by the function of cell.Effectively utilize water liquid removal waste fluid, make that water liquid is keeping dynamic equilibrium state in the body, thus guarantee the carrying out of body normal physiological activity and keeping in the stability of environment.
Says in " element ask vital QI of the body connecting with natural QI opinion " piece of writing: " institute of the moon gives birth to, originally at the five tastes, five ZANG-organs where store the vital essence, being damaged by five flavors ", so " QI and blood to be filling for carefully coordinating five kinds of flavor in foodstuff, solid skeleton and pliable tendons, one's pores will be fine in texture, and sound skeleton and pure essence QI then in this way, sincerely road such as method, length has longevity ".Think according to this theory, human life style, particularly rich and fatty diet and feelings will are forfeited one's integrity chronically, cause on the human body blood source-body fluid unclear, turbid damp is regardless of, and gives birth in the fat, and then condense into the turbid liquid in fat Tianjin and spreading normally, outer and coated internal organs coup injury organs function, interior injection blood vessels then form " blood noxious dampness ", and noxious dampness is exactly due to the turbid liquid in fat Tianjin having a surplus in blood in this blood." interior warp " said: " in the orphan is skillful in, QI consumed in outside ", because moist viscosity is held back impairment of YANG gas, hinder mechanism of qi, it is indefinite to make a return journey in arteries and veins, and Meeting and departing are irregular.Thereby disturb the positive airway dysfunction of human body, can not effectively utilize body fluid and effluent discharge and then cause stagnation of heart-blood, the turbid obturation of expectorant, this is only the basic reason that forms coronary stenosis.Therefore, this pathological changes mechanism is summarised as " the moon is had a surplus, YANG deficiency ".
The present invention adopts Radix Stephaniae Tetrandrae, the Radix Astragali, and Cortex Moutan, Pheretima, Rhizoma Alismatis, Radix Puerariae, Radix Salviae Miltiorrhizae, Fructus Crataegi, the Radix Polygoni Multiflori, medicines such as Rhizoma Chuanxiong are formed by a certain percentage.Radix Stephaniae Tetrandrae wherein, hardship, suffering, cold, return bladder, spleen channel, function tonneau sering, to loose and remove damp and stop up the meridians that stagnate, damp eliminating relieves the pain, the diuresis antiinflammatory." damp eliminating is diuresis not, and Fei Qizhi also "; The Radix Astragali, Gan Wen returns spleen, lung meridian, the warm boundary between muscles space between skin and muscles of energy, tonifying Qi and lifting yang, the diuresis antiinflammatory, the merit of getting its QI can impel body fluid to flow is so amount to the purpose of QI invigorating dampness removing with monarch drug in Radix Stephaniae Tetrandrae, the Radix Astragali side of serving as.Rhizoma Alismatis, sweet light cold, return kidney, urinary bladder channel, the function promoting diuresis to eliminate damp pathogen is let out logical turbid heat; Pheretima, salty-cold, return liver, lung, urinary bladder channel, energy diuresis collateral dredging, Rhizoma Alismatis, Pheretima and Radix Stephaniae Tetrandrae share, and by the diuresis eliminating dampness by diuresis, make the body fluid (waste liquid) of having a surplus from separating down, reach the purpose that purifies blood vessels.Radix Puerariae, Gan Xinping, function eliminating dampness by diuresis and promoting the production of body fluid, the power of the Radix Astragali can be sent out body fluid thoroughly in skin.Cortex Moutan, toil is slightly cold, GUIXIN, liver, kidney channel, function diuresis antiinflammatory, blood circulation promoting and blood stasis dispelling; Radix Salviae Miltiorrhizae, suffering is slightly cold, the GUIXIN Liver Channel, the energy blood circulation promoting and blood stasis dispelling, Cortex Moutan, Radix Salviae Miltiorrhizae are all the product in the blood, get the viscous of the walk help " noxious dampness in the blood " of all medicines of Radix Stephaniae Tetrandrae, accelerate the ability of the turbid malicious waste liquid of body metabolism blood stasis, ministerial drug in the five medicine sides of being.The Radix Polygoni Multiflori, bitter sweet tepor is returned Liver Channel, kidney channel, and the function Yin-nourishing and body fluid promoting nourishes blood, loosening bowel to relieve constipation, can make the body fluid of having a surplus from row between intestinal outlet be arranged, and can prevent all medicine Li Yin again and hinders just anxiety.Fructus Crataegi, sour sweet tepor is returned spleen, stomach, Liver Channel, invigorating the spleen and benefiting QI, promoting digestion and removing stagnation, blood circulation promoting and blood stasis dispelling and diuresis, the meaning of hit " interior warp " " six internal organs paddy, body fluid cloth is raised " is so be adjuvant drug with the Radix Polygoni Multiflori, Fructus Crataegi.Rhizoma Chuanxiong, Xin Wen returns liver, gallbladder, pericardium channel, is the gas medicine in the blood, so think with it and to make, all medicines of rate are directly gone into blood vessels, make in the blood noxious dampness sticking can be rare, stagnate feasible.All medicines share, its duty of the functionary-bank that three warmers " are certainly shown disrespect on ", and " diaphoresis, promoting diuresis to alleviate water retention " is detained " noxious dampness in the blood " nothing." YIN pathogen is gone, then five positive cloth " (" interior warp "), " aqueous vapor is gone, and then the vital essence row is also " (" interior warp ").Fundamentally improve and eliminate the pathomechanism of blood viscous, atheromatous plaque formation, coronary stenosis is progressively removed with logical again.
Studies show that, most of patients is using this product after 4 weeks, clinical symptoms curative effect, electrocardiogram and blood fat change index parameter and all are better than FUFANG DANSHEN PIAN, by showing in the detection to patient's electrocardiogram, liver function, renal function, cholesterol to existing the bad electrocardiogram of coronary artery blood supply after treatment, the blood supply situation has obvious change, the T ripple raises, and former plasma cholesterol rising person treatment has remarkable decline, uses this product treatment liver function and kidney merit are all had no adverse effects.
Specific embodiment:
The present invention is made by following bulk drugs: Radix Stephaniae Tetrandrae 2-10 part, Radix Astragali 2-10 part, Cortex Moutan 1-8 part, Pheretima 1-7 part, Rhizoma Alismatis 1-8 part, Radix Puerariae 1-8 part, Radix Salviae Miltiorrhizae 1-7 part, Fructus Crataegi 1-8 part, Radix Polygoni Multiflori 1-8 part, Rhizoma Chuanxiong 1-6 part;
Preferable range: Radix Stephaniae Tetrandrae 4-8 part, Radix Astragali 4-8 part, Cortex Moutan 2-6 part, Pheretima 1-5 part, Rhizoma Alismatis 2-6 part, Radix Puerariae 2-6 part, Radix Salviae Miltiorrhizae 1-5 part, Fructus Crataegi 2-6 part, Radix Polygoni Multiflori 2-6 part, Rhizoma Chuanxiong 1-4 part.
The present invention produces according to traditional medicine pill preparation method.
Embodiment 1, and the present invention is made by following bulk drugs: 2 parts of Radix Stephaniae Tetrandrae, 2 parts of the Radixs Astragali, 1 part of Cortex Moutan, 1 part of Pheretima, 1 part of Rhizoma Alismatis, 1 part of Radix Puerariae, 1 part of Radix Salviae Miltiorrhizae, 1 part of Fructus Crataegi, 1 part of the Radix Polygoni Multiflori, 1 part of Rhizoma Chuanxiong;
Embodiment 2, and the present invention is made by following bulk drugs: 4 parts of Radix Stephaniae Tetrandrae, 4 parts of the Radixs Astragali, 2 parts of Cortex Moutans, 1 part of Pheretima, 2 parts of Rhizoma Alismatis, 2 parts of Radix Puerariaes, 1 part of Radix Salviae Miltiorrhizae, 2 parts of Fructus Crataegis, 2 parts of the Radixs Polygoni Multiflori, 1 part of Rhizoma Chuanxiong.
Embodiment 3, and the present invention is made by following bulk drugs: 6 parts of Radix Stephaniae Tetrandrae, 6 parts of the Radixs Astragali, 4 parts of Cortex Moutans, 2 parts of Pheretimas, 4 parts of Rhizoma Alismatis, 4 parts of Radix Puerariaes, 2 parts of Radix Salviae Miltiorrhizaes, 4 parts of Fructus Crataegis, 4 parts of the Radixs Polygoni Multiflori, 2 parts of Rhizoma Chuanxiongs.
Embodiment 4, and the present invention is made by following bulk drugs: 8 parts of Radix Stephaniae Tetrandrae, 8 parts of the Radixs Astragali, 6 parts of Cortex Moutans, 5 parts of Pheretimas, 6 parts of Rhizoma Alismatis, 6 parts of Radix Puerariaes, 5 parts of Radix Salviae Miltiorrhizaes, 6 parts of Fructus Crataegis, 6 parts of the Radixs Polygoni Multiflori, 4 parts of Rhizoma Chuanxiongs.
Embodiment 5, and the present invention is made by following bulk drugs: 10 parts of Radix Stephaniae Tetrandrae, 10 parts of the Radixs Astragali, 8 parts of Cortex Moutans, 7 parts of Pheretimas, 8 parts of Rhizoma Alismatis, 8 parts of Radix Puerariaes, 7 parts of Radix Salviae Miltiorrhizaes, 8 parts of Fructus Crataegis, 8 parts of the Radixs Polygoni Multiflori, 6 parts of Rhizoma Chuanxiongs;
The present invention treats 459 examples, and outcome research shows that this medication is imitated reliable, and shorten the course of treatment, and toxic and side effects is little.Now that two groups of clinical observation research reports are as follows:
1, clinical data
The patient is the inpatient, and people's 800 examples of curing the disease altogether between year May in February, 1999 to 2004 enter observation group and matched group respectively by the single, double day of being admitted to hospital at random.Odd-numbered day all enters the treatment group, and this organizes 459 examples, male's 253 examples wherein, and women's 206 examples, age 40-70 year person's 396 examples account for 82.3%.Even-numbered days groups all enters matched group, amounts to 351 examples, wherein male 206 examples, and women 145 examples, 40-70 year person 269 examples account for 76.8%.The coronary heart disease diagnosis standard is a certificate with the 10th edition " practical internal medicine ", and the courses of disease are the shortest 5 months, the longest 12 years before two groups of patient treatments, mostly at 2-7, and angina pectoris number of times every day 1 time, maximum 5 times, average 1-3 time/day; Pain character, position and cardinal symptom are maximum 65.9% with vexed pain, and the pareordia retrosternal pain takes second place 58.8%; Cardinal symptom with cardiopalmus, breathe hard, weak for accounting for 36.1% at most.
Table 1: ordinary circumstance contrast between two groups of groups
| Group | The example number | Sex | Heart rate | The angina pectoris typing | EF value (%) | ||
| The man | The woman | Stable type | Instability mode | ||||
| The treatment group | 459 | 253 | 206 | 71±11 | 367 | 92 | 63+10 |
| Matched group | 351 | 206 | 145 | 71±9 | 280 | 71 | 64±9 |
Above-mentioned two groups of ordinary circumstances are relatively learned by statistics and are handled there was no significant difference, have comparability between group.
2, Therapeutic Method
Method of administration: the experimenter stops using 5 half-life of medicaments for resisting myocardial ischemia at least, to can not the person of stopping using giving nitroglycerin in case of necessity, and writes down its consumption.The treatment group is taken pill of the present invention, every 0.35g, every day 3 times, each 3.Matched group take FUFANG DANSHEN PIAN (Huanghai Sea pharmaceutical Co. Ltd in Shanghai produces, lot number: 031060), every day 3 times, 3 of every days.Be for 4 weeks the course of treatment.
Observational technique: observe two groups of treatment back symptom curative effects, self-symptom integral situation of change, angina pectoris attacks number of times, persistent period, nitroglycerin stop decrement: traces conventional 12 and leads electrocardiogram 1 time weekly, and chemical examination blood fat before and after the treatment.
3, efficacy assessment standard
" angina pectoris and ECG curative effect are said evaluation criteria " that angina pectoris and ECG curative effect criterion are formulated with reference to traditional Chinese medical science combined treatment angina pectoris in 1979 and arrhythmia forum.Oneself's symptom efficacy evaluation: (1) produce effects: treatment back integration descends more than or equal to 1/2.(2) treatment back integration decline person between 1/2-1/3.(3) treatment back integration descends less than 1/3.Oneself's symptom marking standard: 0 minute-asymptomatic; 1 minute-symptom is arranged slightly, degree was slight; 2 minutes-symptom often arranged; 3 minutes-symptom obviously influences work or quality of life.
4, therapeutic outcome
Oneself's doing well,improving: see Table 2, show that the treatment group is better than matched group.Two means are relatively checked with t:
Two rates are relatively checked with X2.
Table 2: two groups of oneself's symptom integral relatively before and after the treatment
| Symptom | The present invention | FUFANG DANSHEN PIAN | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | |
| Uncomfortable in chest | 3.36±1.26 | 1.26±0.97* | 3.30±0.47 | 2.02±0.49*△ |
| Tachypnea | 2.87±0.76 | 1.01±0.30* | 2.84±0.51 | 1.60±0.51*△ |
| Cardiopalmus | 2.66±0.68 | 1.05±0.37* | 2.58±0.51 | 1.61±0.51*△ |
Annotate: compare p＜0.01 before and after relatively reaching treatment of control group before and after the treatment of * treatment group
Compare p＜0.05 between the group of △ treatment back
ECG curative effect: electrocardiogram all has ischemic ST-T to change before and after two groups of treatments, all improve after the treatment, and the treatment group is better than matched group.See Table 3
Table 3: two groups of ECG curative effect relatively
| Group | Produce effects (%) | Effectively (%) | Invalid (%) | Increase the weight of (%) | Total effective rate (%) |
| Treatment group * | 196(42.7) | 240(52.29) | 23(5.01) | 0 | 436(94.99) |
| Matched group | 57(16.24) | 113(32.19) | 110(49.43) | 11(3.13) | 170(48.43) |
*: compare p＜0.01 between group
The blood fat observed result: blood fat situation before and after two groups of treatments is compared observation, and the back treatment group of curing the disease blood fat and improving situation all is better than matched group.
See Table 4
Table 4: the lipid determination result relatively before and after two groups of patient treatments
| Group | The example number | TC | TG | |
| The treatment group | 459 | Before the treatment | 6.18±0.76 | 3.12±1.26 |
| After the treatment | 5.24±0.65** | 1.46±0.76** | ||
| Matched group | 351 | Before the treatment | 6.22±0.82 | 2.98±1.18 |
| After the treatment | 6.10±0.75* | 2.79±1.07* |
Annotate: compare * p＜0.05, * * p＜0.01 with this group treatment front and back.
5, analysis and result:
Clinical observation result shows that the present invention treats coronary heart disease and all significantly is better than FUFANG DANSHEN PIAN in self-doing well,improving, general curative effect, electrocardiogram and blood fat and improving situation.
Claims (3)
1, a kind of medicine pill for the treatment of coronary heart disease is characterized in that being made by following bulk drugs: Radix Stephaniae Tetrandrae 2-10 part, Radix Astragali 2-10 part, Cortex Moutan 1-8 part, Pheretima 1-7 part, Rhizoma Alismatis 1-8 part, Radix Puerariae 1-8 part, Radix Salviae Miltiorrhizae 1-7 part, Fructus Crataegi 1-8 part, Radix Polygoni Multiflori 1-8 part, Rhizoma Chuanxiong 1-6 part.
2, a kind of medicine pill for the treatment of coronary heart disease according to claim 1, it is characterized in that making: Radix Stephaniae Tetrandrae 4-8 part by following bulk drugs, Radix Astragali 4-8 part, Cortex Moutan 2-6 part, Pheretima 1-5 part, Rhizoma Alismatis 2-6 part, Radix Puerariae 2-6 part, Radix Salviae Miltiorrhizae 1-5 part, Fructus Crataegi 2-6 part, Radix Polygoni Multiflori 2-6 part, Rhizoma Chuanxiong 1-4 part.
3, a kind of medicine pill for the treatment of coronary heart disease according to claim 2 is characterized in that being made by following bulk drugs: 6 parts of Radix Stephaniae Tetrandrae, 6 parts of the Radixs Astragali, 4 parts of Cortex Moutans, 2 parts of Pheretimas, 4 parts of Rhizoma Alismatis, 4 parts of Radix Puerariaes, 2 parts of Radix Salviae Miltiorrhizaes, 4 parts of Fructus Crataegis, 4 parts of the Radixs Polygoni Multiflori, 2 parts of Rhizoma Chuanxiongs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410060497 CN1742902A (en) | 2004-09-03 | 2004-09-03 | Chinese medicinal pills for treating coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410060497 CN1742902A (en) | 2004-09-03 | 2004-09-03 | Chinese medicinal pills for treating coronary heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1742902A true CN1742902A (en) | 2006-03-08 |
Family
ID=36138527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410060497 Pending CN1742902A (en) | 2004-09-03 | 2004-09-03 | Chinese medicinal pills for treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1742902A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103055053A (en) * | 2012-12-21 | 2013-04-24 | 王全玉 | Pill cleaning away heart-fire and preparation method thereof |
| CN103860990A (en) * | 2014-03-07 | 2014-06-18 | 陈西成 | Blood-activating and collaterals-dredging pulvis for coronary heart disease and preparation method thereof |
-
2004
- 2004-09-03 CN CN 200410060497 patent/CN1742902A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103055053A (en) * | 2012-12-21 | 2013-04-24 | 王全玉 | Pill cleaning away heart-fire and preparation method thereof |
| CN103860990A (en) * | 2014-03-07 | 2014-06-18 | 陈西成 | Blood-activating and collaterals-dredging pulvis for coronary heart disease and preparation method thereof |
| CN103860990B (en) * | 2014-03-07 | 2016-03-16 | 杨云 | Coronary heart disease promoting blood circulation to remove obstruction in the collateral powder and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103610948B (en) | One treats hypertensive Chinese medicine composition | |
| CN1733242A (en) | Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same | |
| CN1310664C (en) | Chinese medicine capsule for treating cardiac and cerebral vascular diseases and its production process | |
| CN101879272A (en) | Chinese medicinal compound for treating coronary heart diseases, preparation method and application thereof | |
| CN1742902A (en) | Chinese medicinal pills for treating coronary heart disease | |
| CN101700390B (en) | Oral traditional Chinese medicine composition for treating fatty liver | |
| CN102579688B (en) | Blood pressure reducing chrysanthemum and dogbane leaf traditional Chinese medicine preparation | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN1239194C (en) | Chinese patent medicine for treating coronary heart disease and angina pectoris | |
| CN1241603C (en) | Bone joint disease capsule and its manufacturing metod | |
| CN102228618A (en) | Chinese medicinal powder for treating ischemic heart disease | |
| CN105056077A (en) | Traditional Chinese medicine composition for treating functional dyspepsia | |
| CN1294961C (en) | Oral liquid for curing myocardial ischemia and process for preparing the same | |
| CN104056200B (en) | Oral traditional Chinese medicine combination for treating lumbar spinal stenosis | |
| CN1241584C (en) | Chinese patent medicine for treating coronary heart disease and angina pectoris | |
| CN104147335A (en) | Traditional Chinese medicine preparation for treating thoracic obstruction | |
| CN104524096B (en) | A kind ofly treat Chinese medicine preparation of deficiency of the liver and kidney dysmenorrhea and preparation method thereof | |
| CN108096536A (en) | A kind of Chinese medicine composition for treating hemiplegia | |
| CN106606744A (en) | Combination medicament for treating type 2 diabetes mellitus | |
| CN101869689B (en) | External Chinese medicinal composition for treating angina pectoris coronary heart disease | |
| CN1241632C (en) | Chinese patent medicine for treating cardiac function failure and its preparation method | |
| CN100444877C (en) | A Chinese medicine for treating cholecystitis | |
| CN1814171A (en) | Medicine for treating renal incompetence | |
| CN1267126C (en) | Chinese medicine for treating coronary heart disease and angina pectoris | |
| CN104096112A (en) | Traditional Chinese medicine composition for treating angina pectoris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |